A compound for use in the treatment of sickle cell anemia, thalassemia, hereditary spherocytosis, hereditary elliptocytosis, abetalipoproteinemia, nocturnal paroxysmal hemoglobinuria, acquired hemolytic anemia or anemia of chronic diseases comprising a compound of formula (Ib) or a pharmaceutically acceptable salt of the same, wherein: ** Formula ** R1 and R2 are each independently aryl, phenyl, or heteroaryl, optionally substituted with one or more substituents selected from the group consisting of C1-C10 alkyl, C3-C6 alkylene, C2- C10 alkenyl, C2-C10 alkynyl, C1-C10 haloalkyl, C1-C10 dihaloalkyl, C1-C10trihaloalkyl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl, C6-C10 aryl, heterocyclyl, heteroaryl, heteroaryloxy, alkylenedium4, NR4R4 , NCOR4, OCOR4, SCOR4, SOR4, SO2R4, SO2NR4R5, NO2, B (OH) 2, CN, and halogen, R3 and R4 are independently selected from the group consisting of H, C1-C10 alkyl, C2-C10 alkenyl, C2 -C1 0 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl, COR6, F, and CF3, or, R3 and R4, taken together, form C>； = O, R5 and R7 through R10 are independently H, C1-C10 alkyl, or F, R6 is C1-C10 alkyl or C3-C10cycloalkyl, or each of R7 and R8 and R9 and R10, together form C>； = O.Un compuesto para uso en el tratamiento de anemia de células falciformes, talasemia, esferocitosis hereditaria, eliptocitosis hereditaria, abetalipoproteinemia, hemoglobinuria paroxística nocturna, anemia hemolítica adquirida o anemia de enfermedades crónicas que comprende un compuesto de fórmula (Ib) o una sal farmacéuticamente aceptable del mismo, en el que:**Fórmula** R1 y R2 son cada una independientemente arilo, fenilo, o heteroarilo, opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo que consiste en C1-C10 alquilo, C3-C6 alquileno, C2-C10 alquenilo, C2-C10 alquinilo, C1-C10 haloalquilo, C1-C10 dihaloalquilo, C1-C10trihaloalquilo, C3-C10 cicloalquilo, C3-C10 cicloalquenilo, C6-C10 arilo, heterociclilo, heteroarilo, heteroarilóxido, alquilenodioxi, OR4, S
